Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge…
Mylan’s second quarter performance was strong as the company has delivered or exceeded on expectations across all financial metrics, the company’s CEO Heather Bresch said in a press release Monday.
Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%
Proteostasis Therapeutics has started with the phase 2 study of cystic fibrosis treatment by dosing the first patient, after a successful Phase 1 test of PTI’s combinations.
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of…
ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of…
Immix Biopharma, said Tuesday it got a letter from the FDA authorizing it to expand its phase 1b/2a clinical trial of…
Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.
Camurus said Monday that the United States District Court for the District of Columbia granted Braeburn’s motion for summary judgement, vacating the U.S. Food and Drug Administration’s (FDA) decision to block final market approval of Brixadi Monthly.